Drug Development

Articles

The European approval marks the first approval for a biosimilar in that region resulting from the companies’ joint portfolio.

Mylan and Biocon Get Approvals for Biosimilar Insulin Glargine in Europe and Australia

Fujifilm acquires cell culture media companies Irvine Scientific Sales Company and IS Japan.

Fujifilm Expands Bioprocessing Scope

The agency has accepted AstraZeneca’s biologics license application for an investigational leukemia drug candidate and granted it priority review.

FDA Grants Priority Review to AstraZeneca’s Leukemia Biologic

Pfizer transfers CAR-T assets to Allogene Therapeutics under a new alliance to further develop immuno-oncology therapeutics. 

Pfizer Transfers CAR-T Assets to Allogene

Jennifer Markarian is manufacturing reporter for Pharmaceutical Technology.

Particle engineering using jet milling or spray drying can be used to obtain appropriate particle characteristics for inhalation drug products.

Optimizing Particle Engineering Methods for Inhalation Drug Products

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Access to multiple analytical techniques is essential for fully characterizing complex protein formulations.

Multiple Views Deliver Complete Characterization of Protein Particles

CMOs/CDMOs that are easy to work with, have demonstrated performance track records, and plan for the future are preferred.

Unlocking the Best Solution for API Sourcing

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

Accelerated development of new preventives raises challenges for efficient CMC evaluation and production.


Modern Manufacturing Key to More Effective Vaccines

Adeline Siew is editor for Pharmaceutical Technology Europe. She is also science editor for Pharmaceutical Technology.

The high viscosity of highly concentrated monoclonal antibody formulations not only presents processing and storage difficulties, but also formulation and delivery challenges.

Delivering High-Concentration Protein Formulations

Devyn Smith, PhD, is chief operations officer and head of strategy of Sigilon Therapeutics.

Researchers at MIT have discovered a new set of compounds that do not elicit a foreign body response when implanted. These biomaterials permit the development of a new category of treatment with the ability to deliver therapeutics either at a constant rate or under programmable conditions by using implantable cells as protein factories.

Formulation and Drug Delivery